ClinicalTrials.gg

Rhinitis clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 246 studies for Rhinitis across more than 10 countries. 22 are recruiting or about to start. 119 of them are mainly about Rhinitis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its 5 narrower conditions too, such as Rhinitis, Allergic: 1,586 studies, 203 open.

Status

Completed
185
Recruiting
15
Terminated
14
Status unknown
14
Not yet recruiting
7
Withdrawn
7

Phase

Phase 3
48
Phase 2
46
Phase 4
32
Phase 1
14

Where

United States
63
Canada
19
France
13
China
12
Spain
11
United Kingdom
9

Who develops what

Add Rhinitis to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 3 programs from 3 companies, 1 with this as their studies’ main aim; 1 with a live phase 3 study; 0 primary completions in the next 12 months. Compare Inmunotek S.L. and Laboratorios Silanes S.A. de C.V. here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
desloratadineRecent, limited
Evidence
  • NCT06916884 · laboratorios silanes s a de c v · Phase 3 · comparator · “Desloratadine” · registered Apr 2025
  • NCT01108783 · Faes Farma, S.A. · Phase 3 · comparator · “Desloratadine” · registered Apr 2010
Organon & Co.68% of its industry studiesUS: off-patent, 6 generics marketedEU: off-patent, 4 generics authorized11 study
Mometasone FuroateEarlier only
Evidence
  • NCT01038427 · Novartis · Phase 3 · comparator · “Mometasone furoate (Nasonex®) 50 mcg/actuation nasal spray” · registered Dec 2009
  • NCT00562159 · ALK-Abelló A/S · Phase 3 · background · “Mometasone 50 mcg Rescue Treatment” · registered Nov 2007
  • NCT00550550 · ALK-Abelló A/S · Phase 3 · background · “Mometasone furoate 50 mcg Rescue Treatment” · registered Oct 2007
Organon & Co.62% of its industry studiesUS: off-patent, 12 generics marketed00 studies
LoratadineEarlier only
Evidence
  • NCT01413958 · Bayer · Phase 3 · background · “Loratadine” · registered Aug 2011
  • NCT01330017 · Bayer · Phase 2 · background · “Loratadine” · registered Apr 2011
  • NCT00562159 · ALK-Abelló A/S · Phase 3 · background · “Loratadine 10 mg Rescue Treatment” · registered Nov 2007
  • NCT00550550 · ALK-Abelló A/S · Phase 3 · background · “Loratadine Syrup 1 mg/mL Rescue Treatment” · registered Oct 2007
Bayer23% of its industry studiesUS: off-patent, 32 generics marketed00 studies

1 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 3 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (0)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

None in the next 12 months.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Rhinitis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antihistamines 1 open · Corticosteroids 13

Coming up

9studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 9

Who these studies take

Of the 15 Rhinitis studies recruiting now, 4 (27%) set no upper age limit and 10 (67%) stop at 75 or younger. 3 (20%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 4 (27%) take healthy volunteers.

Recruiting studies that take each age, of 15
AgeWomenMen
102 (13%)2 (13%)
1814 (93%)14 (93%)
3015 (100%)15 (100%)
4015 (100%)15 (100%)
5014 (93%)14 (93%)
6513 (87%)13 (87%)
757 (47%)7 (47%)
855 (33%)5 (33%)

Across all 246 studies, recruiting or not: 59% stop at 75 or younger and 49% at 65; 35% take children; <1% are for women only and 1% for men only; 20% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Rhinitis studies take

Of 38 interventional studies with no phase under Rhinitis, half reached primary completion within 11 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Interventional, no phase11 mo5–25 · 38 studies8 mo4–18 · 22 studies—
Observational10 mo7–36 · 13 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 246. Browse all 246 → or search them.